Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 13 (3) , 481-491.e1
Abstract
No abstract availableKeywords
Funding Information
- NIDDK (R01 DK081352)
- NIH
- Medical University of South Carolina (P30 CA138313, P30 GM103339)
- National Center for Research Resources
- Genentech Inc
This publication has 49 references indexed in Scilit:
- Suramin: A Potential Therapy for Diabetic NephropathyPLOS ONE, 2013
- Sphingosine 1-Phosphate Distribution in Human Plasma: Associations with Lipid ProfilesJournal of Lipids, 2012
- Ceramides as modulators of cellular and whole-body metabolismJournal of Clinical Investigation, 2011
- Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study)Metabolomics, 2011
- Accumulation of Long-Chain Glycosphingolipids during Aging Is Prevented by Caloric RestrictionPLOS ONE, 2011
- The role of fatty acid elongation in epidermal structure and functionDermato-Endocrinology, 2011
- Dyslipidemia Associated with Chronic Kidney DiseaseThe Open Cardiovascular Medicine Journal, 2011
- Blood sphingolipidomics in healthy humans: impact of sample collection methodologyJournal of Lipid Research, 2010
- HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphateJournal of Lipid Research, 2010
- Regulation of neutral sphingomyelinase-2 by GSH: a new insight to the role of oxidative stress in aging-associated inflammationJournal of Lipid Research, 2007